Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemoradiotherapy Combined With Slulimumab in the Treatment of First-line Intrahepatic Cholangiocarcinoma: Efficacy and Safety Evaluation of a Phase II Clinical Study

NCT06447454 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT06447454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06447454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemoradiotherapy Combined With Slulimumab in the Treatment of First-line Intrahepatic Cholangiocarcinoma: Efficacy and Safety Evaluation of a Phase II Clinical Study
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
July 1, 2024
Completion date
December 31, 2028
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

icc